112 related articles for article (PubMed ID: 11096354)
1. Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies.
Kurebayashi J; Sonoo H; Inaji H; Nishimura R; Iino Y; Toi M; Kobayashi S; Saeki T
Oncology; 2000; 59 Suppl 1():31-7. PubMed ID: 11096354
[TBL] [Abstract][Full Text] [Related]
2. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
Kai K; Nishimura R; Arima N; Miyayama H; Iwase H
Int J Clin Oncol; 2006 Dec; 11(6):426-33. PubMed ID: 17180510
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors for response to endocrine therapy in patients with recurrent breast cancer.
Sonoo H; Kurebayashi J
Breast Cancer; 2000; 7(4):297-301. PubMed ID: 11114853
[TBL] [Abstract][Full Text] [Related]
4. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
5. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
[TBL] [Abstract][Full Text] [Related]
6. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Cheung KL; Owers R; Robertson JF
Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
[TBL] [Abstract][Full Text] [Related]
7. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy.
Van Den Bossche B; Van Belle S; De Winter F; Signore A; Van de Wiele C
J Nucl Med; 2006 Jan; 47(1):6-13. PubMed ID: 16391181
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
10. Current Status and Controversial Issues concerning Endocrine Therapy for Patients with Recurrent Breast Cancer in Japan.
Sonoo H; Kurebayashi J; Iino Y; Inaji H; Watanabe T; Toi M; Kobayashi S; Sato B; Yoshimoto M
Breast Cancer; 1999 Oct; 6(4):344-350. PubMed ID: 11091741
[TBL] [Abstract][Full Text] [Related]
11. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
14. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
15. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.
Hurvitz SA; Pietras RJ
Cancer; 2008 Nov; 113(9):2385-97. PubMed ID: 18819158
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
17. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy of advanced disease: analysis and implications of the existing data.
Pritchard KI
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):460S-7S. PubMed ID: 12538501
[TBL] [Abstract][Full Text] [Related]
19. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
20. [Endocrine therapy for advanced or recurrent breast cancer].
Sonoo H; Kurebayashi J
Gan To Kagaku Ryoho; 2001 Jul; 28(7):909-16. PubMed ID: 11478139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
